tradingkey.logo
tradingkey.logo
Search

HK Movers | Drugmaker GenFleet Therapeutics Surges 96% in Hong Kong Grey Market

TigerSep 18, 2025 8:15 AM
facebooktwitterlinkedin
View all comments(0)

Chinese biopharmaceutical company GenFleet Therapeutics surged 96% in Hong Kong grey market.

GenFleet Therapeutics focuses on developing novel treatment options in the fields of oncology, covering different lines of treatments of multiple solid tumors, as well as autoimmune and inflammatory diseases.

The firm said it had established a product pipeline consisting of eight product candidates with five under clinical development.

The drugmaker will allocate 71 percent and 19 percent of the net proceeds to fund further development of its two core products and other product candidates, respectively, while 10 percent will be used for working capital and other general corporate purposes.

Last year, the company's net loss expanded 33.3 percent yearly to HK$677.6 million, while its revenue rose 42 percent to HK$104.7 million.

The firm will be listed on Friday.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Comments (0)

Click the $ button, enter the symbol, and select to link a stock, ETF, or other ticker.

0/500
Commenting Guidelines
Loading...

Recommended Articles

tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.